| # | Title | Journal | Year | Citations |
|---|
| 1 | Clinical Trials in Recurrent Ovarian Cancer | International Journal of Gynecological Cancer | 2011 | 186 |
| 2 | CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). | Journal of Clinical Oncology | 2014 | 178 |
| 3 | Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer | Journal of Clinical Oncology | 2012 | 83 |
| 4 | First-Line Therapy in Ovarian Cancer Trials | International Journal of Gynecological Cancer | 2011 | 82 |
| 5 | Serum 25-Hydroxyvitamin D Concentrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial | Cancer Epidemiology Biomarkers and Prevention | 2014 | 63 |
| 6 | Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405 | Journal of Clinical Oncology | 2019 | 51 |
| 7 | A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) | Clinical Cancer Research | 2021 | 46 |
| 8 | Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). | Journal of Clinical Oncology | 2020 | 42 |
| 9 | A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies | Journal of the National Cancer Institute | 2018 | 36 |
| 10 | Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery | Cancer Research | 2020 | 32 |
| 11 | Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial | Cancer Causes and Control | 2016 | 29 |
| 12 | SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma. | Journal of Clinical Oncology | 2021 | 28 |
| 13 | Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. | Journal of Clinical Oncology | 2015 | 27 |
| 14 | SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. | Journal of Clinical Oncology | 2019 | 26 |
| 15 | Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). | Journal of Clinical Oncology | 2020 | 25 |
| 16 | Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL). | Blood | 2009 | 24 |
| 17 | Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502). | Journal of Clinical Oncology | 2017 | 24 |
| 18 | Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience. | Blood | 2005 | 22 |
| 19 | Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211). | Journal of Clinical Oncology | 2020 | 22 |
| 20 | Addressing Skyrocketing Cancer Drug Prices Comes With Tradeoffs | JAMA Oncology | 2016 | 19 |
| 21 | Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma. | Journal of Clinical Oncology | 2021 | 14 |
| 22 | Genome-wide association study of steady-state letrozole concentration in patients with breast cancer. | Journal of Clinical Oncology | 2020 | 14 |
| 23 | Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142. | Journal of Clinical Oncology | 2022 | 13 |
| 24 | INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients. | Journal of Clinical Oncology | 2021 | 12 |
| 25 | Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. | Journal of Clinical Oncology | 2014 | 12 |
| 26 | Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. | Journal of Clinical Oncology | 2015 | 12 |
| 27 | NeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type. | Journal of Clinical Oncology | 2020 | 12 |
| 28 | NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer. | Journal of Clinical Oncology | 2020 | 12 |
| 29 | S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors | Oncologist | 2015 | 10 |
| 30 | Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer. | Journal of Clinical Oncology | 2018 | 9 |
| 31 | SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma | Blood | 2020 | 9 |
| 32 | Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer. | Journal of Clinical Oncology | 2022 | 9 |
| 33 | S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer. | Journal of Clinical Oncology | 2018 | 8 |
| 34 | Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. | Journal of Clinical Oncology | 2022 | 8 |
| 35 | Responding to Patient Requests for Hastened Death: Physician Aid in Dying and the Clinical Oncologist | Journal of Oncology Practice | 2017 | 7 |
| 36 | Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial | Blood | 2019 | 7 |
| 37 | Bladder Cancer Patient Advocacy: A Global Perspective | Bladder Cancer | 2015 | 6 |
| 38 | The Globalization of Cooperative Groups | Seminars in Oncology | 2015 | 6 |
| 39 | Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610. | Journal of Clinical Oncology | 2021 | 6 |
| 40 | Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC). | Journal of Clinical Oncology | 2019 | 6 |
| 41 | INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806. | Journal of Clinical Oncology | 2020 | 6 |
| 42 | Influenza vaccination coverage among US-Mexico land border crossers: 2009 H1N1 pandemic and 2011–2012 influenza season | Travel Medicine and Infectious Disease | 2019 | 5 |
| 43 | Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer | Community Oncology | 2006 | 4 |
| 44 | The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols | International Journal of Radiation Oncology Biology Physics | 2018 | 4 |
| 45 | An in-silico quality assurance study of contouring target volumes in thoracic tumors within a cooperative group setting | Clinical and Translational Radiation Oncology | 2019 | 4 |
| 46 | Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN) | JCO Oncology Practice | 2021 | 4 |
| 47 | U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). | Journal of Clinical Oncology | 2014 | 4 |
| 48 | S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer. | Journal of Clinical Oncology | 2017 | 4 |
| 49 | A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610). | Journal of Clinical Oncology | 2020 | 4 |
| 50 | First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI). | Journal of Clinical Oncology | 2022 | 4 |
